130 related articles for article (PubMed ID: 24482014)
21. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests.
Haug U; Hundt S; Brenner H
Am J Gastroenterol; 2010 Mar; 105(3):682-90. PubMed ID: 19953091
[TBL] [Abstract][Full Text] [Related]
22. Immunochemical fecal occult blood testing is equally sensitive for proximal and distal advanced neoplasia.
de Wijkerslooth TR; Stoop EM; Bossuyt PM; Meijer GA; van Ballegooijen M; van Roon AH; Stegeman I; Kraaijenhagen RA; Fockens P; van Leerdam ME; Dekker E; Kuipers EJ
Am J Gastroenterol; 2012 Oct; 107(10):1570-8. PubMed ID: 22850431
[TBL] [Abstract][Full Text] [Related]
23. The fecal immunochemical test has high accuracy for detecting advanced colorectal neoplasia before age 50.
Kim NH; Park JH; Park DI; Sohn CI; Choi K; Jung YS
Dig Liver Dis; 2017 May; 49(5):557-561. PubMed ID: 28065631
[TBL] [Abstract][Full Text] [Related]
24. Interval fecal immunochemical testing in a colonoscopic surveillance program speeds detection of colorectal neoplasia.
Lane JM; Chow E; Young GP; Good N; Smith A; Bull J; Sandford J; Morcom J; Bampton PA; Cole SR
Gastroenterology; 2010 Dec; 139(6):1918-26. PubMed ID: 20723544
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population.
Launoy GD; Bertrand HJ; Berchi C; Talbourdet VY; Guizard AV; Bouvier VM; Caces ER
Int J Cancer; 2005 Jun; 115(3):493-6. PubMed ID: 15700317
[TBL] [Abstract][Full Text] [Related]
26. [Colorectal cancer screening based on quantitative determining of fecal hemoglobin and transferrin].
Filimonov AV; Kotlyarov EV; Bilan EV
Vopr Onkol; 2015; 61(6):994-7. PubMed ID: 26995994
[TBL] [Abstract][Full Text] [Related]
27. Fecal hemoglobin concentration as a measure of risk to tailor colorectal cancer screening: are we there yet?
Garcia M; Milà N; Binefa G; Benito L; Gonzalo N; Moreno V
Eur J Cancer Prev; 2015 Jul; 24(4):321-7. PubMed ID: 25370684
[TBL] [Abstract][Full Text] [Related]
28. False negative fecal occult blood tests due to delayed sample return in colorectal cancer screening.
van Rossum LG; van Rijn AF; van Oijen MG; Fockens P; Laheij RJ; Verbeek AL; Jansen JB; Dekker E
Int J Cancer; 2009 Aug; 125(4):746-50. PubMed ID: 19408302
[TBL] [Abstract][Full Text] [Related]
29. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon.
Lieberman DA; Weiss DG;
N Engl J Med; 2001 Aug; 345(8):555-60. PubMed ID: 11529208
[TBL] [Abstract][Full Text] [Related]
30. Can quantification of faecal occult blood predetermine the need for colonoscopy in patients at risk for non-syndromic familial colorectal cancer?
Levi Z; Rozen P; Hazazi R; Vilkin A; Waked A; Maoz E; Birkenfeld S; Niv Y
Aliment Pharmacol Ther; 2006 Nov; 24(10):1475-81. PubMed ID: 17032281
[TBL] [Abstract][Full Text] [Related]
31. Random comparison of repeated faecal immunochemical testing at different intervals for population-based colorectal cancer screening.
van Roon AH; Goede SL; van Ballegooijen M; van Vuuren AJ; Looman CW; Biermann K; Reijerink JC; Mannetje H'; van der Togt AC; Habbema JD; van Leerdam ME; Kuipers EJ
Gut; 2013 Mar; 62(3):409-15. PubMed ID: 22387523
[TBL] [Abstract][Full Text] [Related]
32. Quality of colonoscopy in an organised colorectal cancer screening programme with immunochemical faecal occult blood test: the EQuIPE study (Evaluating Quality Indicators of the Performance of Endoscopy).
Zorzi M; Senore C; Da Re F; Barca A; Bonelli LA; Cannizzaro R; Fasoli R; Di Furia L; Di Giulio E; Mantellini P; Naldoni C; Sassatelli R; Rex D; Hassan C; Zappa M;
Gut; 2015 Sep; 64(9):1389-96. PubMed ID: 25227521
[TBL] [Abstract][Full Text] [Related]
33. Lower risk of advanced neoplasia among patients with a previous negative result from a fecal test for colorectal cancer.
Denters MJ; Deutekom M; Bossuyt PM; Stroobants AK; Fockens P; Dekker E
Gastroenterology; 2012 Mar; 142(3):497-504. PubMed ID: 22108194
[TBL] [Abstract][Full Text] [Related]
34. [Chemical or immunological tests for the detection of fecal occult blood in colorectal cancer screening?].
Quintero E
Gastroenterol Hepatol; 2009 Oct; 32(8):565-76. PubMed ID: 19577340
[TBL] [Abstract][Full Text] [Related]
35. Factors associated with false-positive and false-negative fecal immunochemical test results for colorectal cancer screening.
Wong MC; Ching JY; Chan VC; Lam TY; Luk AK; Ng SS; Sung JJ
Gastrointest Endosc; 2015 Mar; 81(3):596-607. PubMed ID: 25293827
[TBL] [Abstract][Full Text] [Related]
36. Sensitivity and Specificity of Community Fecal Immunotesting Screening for Colorectal Carcinoma in a High-Risk Canadian Population.
Crouse AL; De Koning L; Sadrzadeh SM; Naugler C
Arch Pathol Lab Med; 2015 Nov; 139(11):1441-5. PubMed ID: 26516941
[TBL] [Abstract][Full Text] [Related]
37. Predictive power of quantitative and qualitative fecal immunochemical tests for hemoglobin in population screening for colorectal neoplasm.
Huang Y; Li Q; Ge W; Cai S; Zhang S; Zheng S
Eur J Cancer Prev; 2014 Jan; 23(1):27-34. PubMed ID: 23942476
[TBL] [Abstract][Full Text] [Related]
38. Prospective evaluation of fecal calprotectin as a screening biomarker for colorectal neoplasia.
Limburg PJ; Devens ME; Harrington JJ; Diehl NN; Mahoney DW; Ahlquist DA
Am J Gastroenterol; 2003 Oct; 98(10):2299-305. PubMed ID: 14572583
[TBL] [Abstract][Full Text] [Related]
39. A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial.
Denters MJ; Deutekom M; Bossuyt PM; Fockens P; Dekker E
Eur J Cancer Prev; 2013 Jul; 22(4):299-304. PubMed ID: 23169243
[TBL] [Abstract][Full Text] [Related]
40. Test performance of immunologic fecal occult blood testing and sigmoidoscopy compared with primary colonoscopy screening for colorectal advanced adenomas.
Khalid-de Bakker CA; Jonkers DM; Sanduleanu S; de Bruïne AP; Meijer GA; Janssen JB; van Engeland M; Stockbrügger RW; Masclee AA
Cancer Prev Res (Phila); 2011 Oct; 4(10):1563-71. PubMed ID: 21750209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]